Johnson & Johnson Gross Profit 2010-2022 | JNJ

Johnson & Johnson annual/quarterly gross profit history and growth rate from 2010 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Johnson & Johnson gross profit for the quarter ending March 31, 2022 was $15.828B, a 3.74% increase year-over-year.
  • Johnson & Johnson gross profit for the twelve months ending March 31, 2022 was $64.490B, a 15.6% increase year-over-year.
  • Johnson & Johnson annual gross profit for 2021 was $63.92B, a 18.03% increase from 2020.
  • Johnson & Johnson annual gross profit for 2020 was $54.157B, a 0.63% decline from 2019.
  • Johnson & Johnson annual gross profit for 2019 was $54.503B, a 0.02% increase from 2018.
Johnson & Johnson Annual Gross Profit
(Millions of US $)
2021 $63,920
2020 $54,157
2019 $54,503
2018 $54,490
2017 $51,011
2016 $50,101
2015 $48,538
2014 $51,585
2013 $48,970
2012 $45,566
2011 $44,670
2010 $42,795
2009 $43,450
Johnson & Johnson Quarterly Gross Profit
(Millions of US $)
2022-03-31 $15,828
2021-12-31 $16,849
2021-09-30 $16,088
2021-06-30 $15,725
2021-03-31 $15,258
2020-12-31 $14,661
2020-09-30 $14,110
2020-06-30 $11,757
2020-03-31 $13,629
2019-12-31 $13,613
2019-09-30 $13,862
2019-06-30 $13,622
2019-03-31 $13,406
2018-12-31 $13,433
2018-09-30 $13,759
2018-06-30 $13,903
2018-03-31 $13,395
2017-12-31 $12,936
2017-09-30 $12,725
2017-06-30 $12,993
2017-03-31 $12,357
2016-12-31 $12,468
2016-09-30 $12,334
2016-06-30 $13,146
2016-03-31 $12,153
2015-12-31 $12,138
2015-09-30 $11,878
2015-06-30 $12,430
2015-03-31 $12,092
2014-12-31 $12,401
2014-09-30 $13,068
2014-06-30 $13,456
2014-03-31 $12,660
2013-12-31 $12,400
2013-09-30 $12,231
2013-06-30 $12,388
2013-03-31 $11,951
2012-12-31 $11,555
2012-09-30 $11,455
2012-06-30 $11,332
2012-03-31 $11,224
2011-12-31 $10,917
2011-09-30 $10,933
2011-06-30 $11,425
2011-03-31 $11,395
2010-12-31 $10,604
2010-09-30 $10,388
2010-06-30 $10,700
2010-03-31 $11,103
2009-12-31 $11,239
2009-09-30 $10,647
2009-06-30 $10,789
2009-03-31 $10,775
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $465.705B $93.775B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Pfizer (PFE) United States $294.404B 10.27
Eli Lilly (LLY) United States $283.955B 33.50
AbbVie (ABBV) United States $266.851B 11.70
Merck (MRK) United States $236.570B 13.36
Novartis AG (NVS) Switzerland $200.009B 14.40
GlaxoSmithKline (GSK) United Kingdom $113.161B 13.21
Novo Nordisk (NVO) Denmark $0.000B 32.07